Subscribe to RSS
DOI: 10.4103/ijmpo.ijmpo_244_20
Total Pelvic Exenteration in Leiomyosarcoma - A Case Report
Financial support and sponsorship Nil.
Abstract
Locally advanced high-grade leiomyosarcomas (LMS) with visceral involvement are difficult to manage. Here, we present a case of locally advanced high-grade sarcoma where total pelvic exenteration was undertaken to achieve complete cytoreduction. A 54-year-old lady with a prior history of hysterectomy and bilateral salpingoophorectomy done 8 years back for heavy menstrual bleeding presented to us with an abdomino-pelvic mass. Magnetic resonance imaging of the abdomen suggested large heterogeneous pelvic mass displacing urinary bladder anteriorly and abutting recto-sigmoid posteriorly with no luminal involvement. There was bilateral hydronephrosis. Computed tomography of the thorax revealed no evidence of metastatic disease. A review of previous biopsy and a repeat ultrasound-guided biopsy from the pelvic mass done at our institute suggested spindle-cell neoplasm. In view of pelvis confined disease in a young woman with well-preserved general condition, decision for surgical excision was taken. She underwent total pelvic exenteration with en bloc removal of mass, bladder, and involved portion of recto-sigmoid as the disease was infiltrating both the bladder and the recto-sigmoid. Her postoperative course was turbulent, but she recovered fully and was discharged 20 days after surgery. The operative specimen histopathology revealed high-grade LMS. She received four cycles of adjuvant chemotherapy and thereafter was kept on follow-up. Although she was clinically doing well, her general condition never improved beyond Eastern cooperative oncology Group 2. She also had persistent depressive symptoms. After 14 months of completion of treatment, she recurred with a huge abdominal disease. In view of her general condition and huge disease volume, decision was taken for supportive care only. LMS in advanced stages are difficult to manage. Even after aggressive management with radical exenterative surgery and chemotherapy, we could achieve only temporary control of locally advanced LMS.
Publication History
Received: 19 May 2020
Accepted: 06 August 2020
Article published online:
14 May 2021
© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009; 54: 355-64
- 2 Sinha S, Kurman RJ, Carcangiu ML, Herrington CS, Young RH. editors WHO Classification of Tumours of Female Reproductive Organs. Lyon: IARC; 2014. 4. 135-48
- 3 Schneider N, Strauss DC, Smith MJ, Miah AB, Zaidi S, Benson C. et al. The Adequacy of core biopsy in the assessment of smooth muscle neoplasms of soft tissues: Implications for treatment and prognosis. Am J Surg Pathol 2017; 41: 923-31
- 4 DeVita VTJr, Lawrence TS, Rosenberg SA. Devita, Hellman, and Rosenberg's. Cancer: Principles & Practice of Oncology. 11th ed.Place of Publication Lippincott Williams & Wilkins (LWW); 2018
- 5 Priya BS, Kathiresan K, Anandan H. Retroperitoneal soft tissue sarcoma: An analysis of surgical and adjuvant chemotherapy. Int J Sci Stud 2017; 4: 154-7
- 6 Dumitra S, Gronchi A. The diagnosis and management of retroperitoneal sarcoma. Oncol J 2018; 32: 464-9
- 7 Leitao MMJr, Zivanovic O, Chi DS, Hensley ML, O'Cearbhaill R, Soslow RA. et al Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol 2012; 125: 409-13
- 8 Gortzak E, Azzarelli A, Buesa J, Bramwell VH, van Coevorden F, van Geel AN. et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 2001; 37: 1096-103
- 9 Gronchi A, Ferrari S, Qsuagliuolo V, Broto JM, Pousa AL, Grigani G. et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): An international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 2017; 18: 812-22
- 10 Surgery With or Without Neoadjuvant Chemotherapy in High Risk Retroperitoneal Sarcoma (STRASS2).ClinicalTrials.gov Identifier: NCT04031677. Available from: https://clinicaltrials.gov/ct2/show/NCT04031677. [Last update on 2020 May 14]